Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson JNJ, Pfizer PFE, Roche RHHBY, AbbVie ABBV and Sanofi SNY.
This week, Johnson & Johnson began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s gene therapy for hemophilia, Roche’s breast cancer drug and AbbVie’s Parkinson’s treatment. Sanofi said it is considering selling a 50% stake in its consumer healthcare business (“CHC”), which it intends to separate.
Here's a recap of the week’s most important stories.
Johnson & Johnson’s third-quarter results were strong as it beat estimates for both earnings and sales. JNJ’s Innovative Medicines segment outperformed expectations while MedTech underperformed. Sales in Innovative Medicines segment rose 4.9% year over year to $14.58 billion. MedTech segment sales came in at $7.89 billion, up 5.8% from the year-ago period.
Johnson & Johnson’ raised its total revenue expectation for the year as it expects an improved performance in the rest of the year. However, the company lowered its adjusted earnings expectation as its expectation of a better operational performance was partially offset by costs associated with the recent acquisition of private medical device company V-Wave.
Total revenues are expected in the range of $88.4 billion-$88.8 billion for 2024, up from $88.0 billion-$88.4 billion expected previously. The adjusted earnings per share guidance was lowered from a range of $9.97-$10.07 to $9.88-$9.98 per share.
The FDA granted approval to Pfizer’s anti-TFPI inhibitor, marstacimab, for the treatment of hemophilia A and B. The drug will be marketed by the name of Hympavzi as a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and adolescents with hemophilia A or B without inhibitors. Hympavzi’s approval was based on positive data from the phase III BASIS study.
A marketing authorization application (MAA) for marstacimab is also under review in the EU. The European Commission’s decision on the MAA is expected by the first quarter of 2025. Hympavzi is Pfizer’s second hemophilia treatment to be approved this year. Beqvez/Durveqtix (fidanacogene elaparvovec), a one-time gene therapy for hemophilia B, was approved by the FDA in April 2024.
The FDA approved AbbVie’s Vyalev (foscarbidopa and foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Vyalev is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for advanced Parkinson's disease, which allows continuous delivery of levodopa in the morning, day and night. The approval was based on data from a pivotal phase III study, which compared the subcutaneous infusion of Vyalev to oral immediate-release carbidopa/levodopa.
The study data showed that patients who were treated with Vyalev experienced superior improvement in "on" time without troublesome dyskinesia versus oral medications. "On" time refers to the periods of time when patients are experiencing optimal motor symptom control. AbbVie said that Medicare is expected to cover the drug from the second half of 2025. Vyalev was launched by the name of Produodopa in the European Union in January.
The FDA also approved Roche’s investigational breast cancer drug, inavolisib, to be sold under the brand name Itovebi. It is approved in combination with Pfizer’s Ibrance (palbociclib) and fulvestrant for treating advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. Itovebi is Roche’s first targeted therapy approved for people with HR-positive disease, which is the most prevalent breast cancer subtype. The approval was based on data from the phase III INAVO120 study.
Sanofi announced that it is in discussion to sell a 50% controlling stake in Opella, its CHC business. Sanofi announced its intention to separate its CHC unit last year through the creation of a publicly listed entity headquartered in Paris called Opella.
Sanofi is in negotiations with a U.S-based investment company, CD&R, for the potential sale of a controlling stake and an update will be provided when a final decision is made. With the separation of its consumer health unit, Sanofi joins several other large drugmakers like J&J, GSK and Pfizer, which have also sold off their consumer health units to focus on their core pharmaceuticals business.
The NYSE ARCA Pharmaceutical Index declined 0.5% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
In the last five trading sessions, Johnson & Johnson rose the most (2.4%), while AbbVie declined the most (3.0%).
In the past six months, while Lilly rose the most (26.3%), Merck declined the most (12.7%).
(See the last pharma stock roundup here: FDA Approves SNY’s Dupixent for COPD & More)
Watch this space for Sanofi and Roche’s third-quarter earnings update and regular pipeline and regulatory updates next week.
Pfizer, AbbVie, JNJ, Roche and Sanofi have a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。